Takeda Bulks Up In Obesity With Orexigen Deal
This article was originally published in PharmAsia News
Executive Summary
Takeda, already a strong player in diabetes, is looking to be a leader in obesity as well. Obesity is a risky area of drug development, given regulatory concerns about safety and efficacy, not to mention payer resistance. But despite those roadblocks, Takeda added to its substantial obesity pipeline through a deal with Orexigen Therapeutics, announced Sept. 2
You may also be interested in...
Takeda Caught Surprised By Outcomes For Two Key Products
TOKYO - Takeda Pharmaceuticals' highly positive Phase III data for antibody drug conjugate SGN-35 (brentuximab vedotin) - partnered with Seattle Genetics - is a bright spot for the company after a "complete response" letter to partner Orexigen for obesity drug Contrave (bupropion/naltrexone)
Takeda Caught Surprised By Outcomes For Two Key Products
TOKYO - Takeda Pharmaceuticals' highly positive Phase III data for antibody drug conjugate SGN-35 (brentuximab vedotin) - partnered with Seattle Genetics - is a bright spot for the company after a "complete response" letter to partner Orexigen for obesity drug Contrave (bupropion/naltrexone)
FDA Panel Backs Approval Of Takeda/Orexigen's Obesity Drug Contrave
The promise of a randomized clinical trial to examine the cardiovascular risks of Orexigen's weight-loss drug Contrave - inlicensed by Takeda for North American commercialization and development rights - prompted a 13-7 vote in favor of approval by the agency's Endocrinologic and Metabolic Drugs Advisory Committee Dec. 7